Adaptive Biotechnologies Financials

Earnings View

Profitability View

Liquidity View

Fundamentals View

Competition View

Adaptive Biotechnologies Company Summary

Adaptive Biotechnologies competes with Valneva SE, Dominari Holdings, Home Depot, Johnson Johnson, and Verizon Communications. Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington. Adaptive Biotechnologies operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 858 people.

Adaptive Biotechnologies Key Financial Ratios

Generally speaking, Adaptive Biotechnologies' financial ratios allow both analysts and investors to convert raw data from Adaptive Biotechnologies' financial statements into concise, actionable information that can be used to evaluate the performance of Adaptive Biotechnologies over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Adaptive Biotechnologies reports annually and quarterly.

Adaptive Biotechnologies Key Balance Sheet Accounts

Adaptive Biotechnologies Key Income Statement Accounts

Adaptive Biotechnologies Key Cash Accounts

Adaptive Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Adaptive Biotechnologies's current stock value. Our valuation model uses many indicators to compare Adaptive Biotechnologies value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Adaptive Biotechnologies competition to find correlations between indicators driving Adaptive Biotechnologies's intrinsic value. More Info.Adaptive Biotechnologies Corp is number one stock in working capital category among related companies. It is number one stock in retained earnings category among related companies . Adaptive Biotechnologies Working Capital is comparatively stable at the moment as compared to the past year. Adaptive Biotechnologies reported Working Capital of 452.36 Million in 2022. Comparative valuation analysis is a catch-all model that can be used if you cannot value Adaptive Biotechnologies by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Adaptive Biotechnologies' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Adaptive Biotechnologies' earnings, one of the primary drivers of an investment's value.

Adaptive Biotechnologies Systematic Risk

What exactly are Adaptive Biotechnologies Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Adaptive Biotechnologies' income statement, its balance sheet, and the statement of cash flows. Potential Adaptive Biotechnologies investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Adaptive Biotechnologies investors may use each financial statement separately, they are all related. The changes in Adaptive Biotechnologies's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Adaptive Biotechnologies's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.

There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Adaptive Biotechnologies is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Adaptive has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it.

Along with financial statement analysis, the daily predictive indicators of Adaptive Biotechnologies help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Adaptive Biotechnologies Corp. We use our internally-developed statistical techniques to arrive at the intrinsic value of Adaptive Biotechnologies Corp based on widely used predictive technical indicators. In general, we focus on analyzing Adaptive Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Adaptive Biotechnologies's daily price indicators and compare them against related drivers.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adaptive Biotechnologies Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.

When running Adaptive Biotechnologies' price analysis, check to measure Adaptive Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptive Biotechnologies is operating at the current time. Most of Adaptive Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Adaptive Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptive Biotechnologies' price. Additionally, you may evaluate how the addition of Adaptive Biotechnologies to your portfolios can decrease your overall portfolio volatility.

Is Adaptive Biotechnologies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adaptive Biotechnologies. If investors know Adaptive will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adaptive Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Adaptive Biotechnologies is measured differently than its book value, which is the value of Adaptive that is recorded on the company's balance sheet. Investors also form their own opinion of Adaptive Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Adaptive Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adaptive Biotechnologies' market value can be influenced by many factors that don't directly affect Adaptive Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Adaptive Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adaptive Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adaptive Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.